The Board of Baytacare Pharmaceutical Co., Ltd. announced that, with effect from 9 July 2018, Mr. Fang Yao, an executive Director, has been appointed as an authorized representative of the Company in place of Mr. Ng Chenhuei for the purposes of Rule 5.24 of the GEM Listing Rules. Mr. Ng Chenhuei will continue to serve as the company secretary of the Company.